Immune-checkpoint inhibitors and metastatic prostate cancer therapy: learning by making mistakes

Since the evidence that Ipilimumab, a human monoclonal antibody (mAb) inhibiting cytotoxic T ‑lymphocyte antigen 4 (CTLA‑4), improved survival in patients with metastatic melanoma [1], the interest of the scientific community for tumor immunology and immunotherapeutic strategies in the last decade has rapidly increased. Nowadays, multiple immunotherapies have been approved for many soli d and hematologic malignancies (i.e. kidney cancer, melanoma, head and neck cancer, urothelial cancer, lung cancer, Hodgkin’s lymphoma) [2].

Source: Cancer Treatment Reviews - June 9, 2020 Category: Cancer & Oncology Authors: Claps M élanie, Mennitto Alessia, Guadalupi Valentina, Sepe Pierangela, Stellato Marco, Zattarin Emma, Gillessen Sommer Silke, Sternberg Cora N, Berruti Alfredo, De Braud Filippo Guglielmo Maria, Verzoni Elena, Procopio Giuseppe Tags: Anti-tumour Treatment Source Type: research